Amgen Stock Soars to Intraday High with 4.84% Surge

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a significant uptick in its stock performance today, gaining 4.84% and reaching an intraday high of USD 358.44. This surge comes amid a backdrop of strong financial metrics, including a high return on capital employed (ROCE) of 22.31%, indicating effective management efficiency. Over the past year, Amgen has delivered a return of 21.33%, slightly trailing the S&P 500's performance of 22.78%. However, the company has shown resilience with a year-to-date performance of 8.17%, outperforming the S&P 500's 8.02%. Notably, Amgen's profits have surged by 62.9% over the last year, contributing to a favorable PEG ratio of 0.3, suggesting a solid valuation relative to its growth. The company also boasts a robust dividend payout ratio of 75.36%, with a dividend per share of USD 4.32, reflecting its commitment to returning value to shareholders. With institutional holdings at a high 83.15%, Amgen continues to maintain a strong market position, supported by a market capitalization of USD 188,011 million.